HPV16 Down-Regulates the Insulin-Like Growth Factor Binding Protein 2 to Promote Epithelial Invasion in Organotypic Cultures

English version České info

The human papillomaviruses (HPV) are the etiological agents of cervical cancer and the disease progresses through the pre-malignant phases of cervical intraepithelial neoplasia I, II and III (CINI-III), before becoming an invasive carcinoma. Therefore identifying factors, which regulate the transition through the premalignant phases and onto invasive cancer would be of importance clinically, to identify patients at risk of progressing from CIN I to CIN III. We show that expression of E6 and E7 proteins from the high risk HPV16, causes reduced expression of the IGF binding protein 2 (IGFBP2) and this correlates with progression from CIN I to CIN III. By modulating IGFBP2 levels in epithelial cells, we have demonstrated that reduction of IGFBP2 levels is a driving event in epithelial invasion. We have gone on to show that de-regulation of expression of IGFBP2 is due to histone deacetylation of the promoter, which can be reversed by histone deacetylase inhibitors.

Vyšlo v časopise: HPV16 Down-Regulates the Insulin-Like Growth Factor Binding Protein 2 to Promote Epithelial Invasion in Organotypic Cultures. PLoS Pathog 11(6): e32767. doi:10.1371/journal.ppat.1004988
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004988

Souhrn

Zdroje

1. Hudson JB, Bedell MA, McCance DJ, Laiminis LA. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol. 1990;64(2):519–26. 2153221; PubMed Central PMCID: PMCPMC249139.

2. Münger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989;63(10):4417–21. 2476573; PubMed Central PMCID: PMCPMC251060.

3. Rudlowski C, Becker AJ, Schroder W, Rath W, Büttner R, Moser M. GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am J Clin Pathol. 2003;120(5):691–8. doi: 10.1309/4KYN-QM58-62JW-2GD7 14608894.

4. Dürst M, Dzarlieva-Petrusevska RT, Boukamp P, Fusenig NE, Gissmann L. Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene. 1987;1(3):251–6. 2838778.

5. McCance DJ, Kopan R, Fuchs E, Laimins LA. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc Natl Acad Sci U S A. 1988;85(19):7169–73. 2459699; PubMed Central PMCID: PMCPMC282145.

6. Menges CW, Baglia LA, Lapoint R, McCance DJ. Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. Cancer Res. 2006;66(11):5555–9. doi: 10.1158/0008-5472.CAN-06-0499 16740689.

7. Wong PP, Pickard A, McCance DJ. p300 alters keratinocyte cell growth and differentiation through regulation of p21(Waf1/CIP1). PLoS One. 2010;5(1):e8369. doi: 10.1371/journal.pone.0008369 20084294; PubMed Central PMCID: PMCPMC2805707.

8. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11–22. doi: 10.1038/nrc2050 17186016.

9. Wentzensen N. Triage of HPV-positive women in cervical cancer screening. Lancet Oncol. 2013;14(2):107–9. doi: 10.1016/S1470-2045(12)70568-5 23261357.

10. Pastuszak-Lewandoska D, Bartosińska-Dyc A, Migdalska-Sęk M, Czarnecka KH, Nawrot E, Domańska D, et al. HPV16 E6*II gene expression in intraepithelial cervical lesions as an indicator of neoplastic grade: a pilot study. Med Oncol. 2014;31(3):842. doi: 10.1007/s12032-014-0842-6 24436016.

11. Shulzhenko N, Lyng H, Sanson GF, Morgun A. Ménage à trois: an evolutionary interplay between human papillomavirus, a tumor, and a woman. Trends Microbiol. 2014. doi: 10.1016/j.tim.2014.02.009 24674660.

12. Overmeer RM, Henken FE, Bierkens M, Wilting SM, Timmerman I, Meijer CJ, et al. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol. 2009;219(3):327–36. doi: 10.1002/path.2598 19662663.

13. Kuramoto H, Hongo A, Liu YX, Ojima Y, Nakamura K, Seki N, et al. Immunohistochemical evaluation of insulin-like growth factor I receptor status in cervical cancer specimens. Acta Med Okayama. 2008;62(4):251–9. 18766208.

14. Schrevel M, Gorter A, Kolkman-Uljee SM, Trimbos JB, Fleuren GJ, Jordanova ES. Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer. Mod Pathol. 2011;24(5):720–8. doi: 10.1038/modpathol.2010.239 21252859.

15. Su PH, Lin YW, Huang RL, Liao YP, Lee HY, Wang HC, et al. Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer. Oncogene. 2013;32(1):15–26. doi: 10.1038/onc.2012.29 22330137.

16. Lin Z, Bazzaro M, Wang MC, Chan KC, Peng S, Roden RB. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res. 2009;15(2):570–7. doi: 10.1158/1078-0432.CCR-08-1813 19147762; PubMed Central PMCID: PMCPMC2714480.

17. Hyland PL, McDade SS, McCloskey R, Dickson GJ, Arthur K, McCance DJ, et al. Evidence for alteration of EZH2, BMI1, and KDM6A and epigenetic reprogramming in human papillomavirus type 16 E6/E7-expressing keratinocytes. J Virol. 2011;85(21):10999–1006. doi: 10.1128/JVI.00160-11 21865393; PubMed Central PMCID: PMCPMC3194988.

18. McLaughlin-Drubin ME, Crum CP, Münger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci U S A. 2011;108(5):2130–5. doi: 10.1073/pnas.1009933108 21245294; PubMed Central PMCID: PMCPMC3033314.

19. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014;14(6):395–405. doi: 10.1038/nrc3728 24854082.

20. Gius D, Funk MC, Chuang EY, Feng S, Huettner PC, Nguyen L, et al. Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res. 2007;67(15):7113–23. doi: 10.1158/0008-5472.CAN-07-0260 17671178.

21. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res. 2001;61(24):8601–10. 11751371.

22. Pickard A, Cichon AC, Barry A, Kieran D, Patel D, Hamilton P, et al. Inactivation of Rb in stromal fibroblasts promotes epithelial cell invasion. EMBO J. 2012;31(14):3092–103. doi: 10.1038/emboj.2012.153 22643222; PubMed Central PMCID: PMCPMC3400012.

23. Chapman S, Liu X, Meyers C, Schlegel R, McBride AA. Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor. J Clin Invest. 2010;120(7):2619–26. doi: 10.1172/JCI42297 20516646; PubMed Central PMCID: PMCPMC2898606.

24. Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniyam S, Schneider A, et al. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer. 2008;47(9):755–65. doi: 10.1002/gcc.20577 18506748.

25. Ernst CW, White ME. Hormonal regulation of IGF-binding protein-2 expression in proliferating C2C12 myoblasts. J Endocrinol. 1996;149(3):417–29. 8691100.

26. Schmid C, Schläpfer I, Waldvogel M, Meier PJ, Schwander J, Böni-Schnetzler M, et al. Differential regulation of insulin-like growth factor binding protein (IGFBP)-2 mRNA in liver and bone cells by insulin and retinoic acid in vitro. FEBS Lett. 1992;303(2–3):205–9. 1376696.

27. Chiba T, Yokosuka O, Fukai K, Kojima H, Tada M, Arai M, et al. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology. 2004;66(6):481–91. doi: 10.1159/000079503 15452378.

28. Yang YJ, Song TY, Park J, Lee J, Lim J, Jang H, et al. Menin mediates epigenetic regulation via histone H3 lysine 9 methylation. Cell Death Dis. 2013;4:e583. doi: 10.1038/cddis.2013.98 23579270; PubMed Central PMCID: PMCPMC3668625.

29. Biernacka KM, Uzoh CC, Zeng L, Persad RA, Bahl A, Gillatt D, et al. Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocr Relat Cancer. 2013;20(5):741–51. doi: 10.1530/ERC-13-0077 23959956.

30. Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57–74. doi: 10.1038/nature11247 22955616; PubMed Central PMCID: PMCPMC3439153.

31. Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell. 2010;18(5):436–47. doi: 10.1016/j.ccr.2010.10.022 21075309; PubMed Central PMCID: PMCPMC3004468.

32. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129(4):823–37. doi: 10.1016/j.cell.2007.05.009 17512414.

33. Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Huebert DJ, et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell. 2005;120(2):169–81. doi: 10.1016/j.cell.2005.01.001 15680324.

34. Karagianni P, Wong J. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene. 2007;26(37):5439–49. doi: 10.1038/sj.onc.1210612 17694085.

35. Guenther MG, Barak O, Lazar MA. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol. 2001;21(18):6091–101. 11509652; PubMed Central PMCID: PMCPMC87326.

36. Kiepe D, Ulinski T, Powell DR, Durham SK, Mehls O, Tönshoff B. Differential effects of insulin-like growth factor binding proteins-1, -2, -3, and -6 on cultured growth plate chondrocytes. Kidney Int. 2002;62(5):1591–600. doi: 10.1046/j.1523-1755.2002.00603.x 12371959.

37. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824–54. 12466191.

38. Gockerman A, Prevette T, Jones JI, Clemmons DR. Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I and IGF-II. Endocrinology. 1995;136(10):4168–73. 7545099.

39. Moreno-Acosta P, Gamboa O, Sanchez de Gomez M, Cendales R, Diaz GD, Romero A, et al. IGF1R gene expression as a predictive marker of response to ionizing radiation for patients with locally advanced HPV16-positive cervical cancer. Anticancer Res. 2012;32(10):4319–25. 23060553.

40. Butticè G, Duterque-Coquillaud M, Basuyaux JP, Carrère S, Kurkinen M, Stéhelin D. Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene. 1996;13(11):2297–306. 8957070.

41. Ropiquet F, Huguenin S, Villette JM, Ronflé V, Le Brun G, Maitland NJ, et al. FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells. Int J Cancer. 1999;82(2):237–43. 10389758.

42. Maretzky T, Evers A, Zhou W, Swendeman SL, Wong PM, Rafii S, et al. Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nat Commun. 2011;2:229. doi: 10.1038/ncomms1232 21407195; PubMed Central PMCID: PMCPMC3074487.

43. Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res. 2010;16(13):3378–89. doi: 10.1158/1078-0432.CCR-10-0014 20570921; PubMed Central PMCID: PMCPMC2896550.

44. Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, et al. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer. 2013;132(1):198–207. doi: 10.1002/ijc.27608 22532127.

45. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–9. doi: 10.1016/S1470-2045(10)70017-6 20451455.

46. Thurlow JK, Peña Murillo CL, Hunter KD, Buffa FM, Patiar S, Betts G, et al. Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. J Clin Oncol. 2010;28(17):2881–8. doi: 10.1200/JCO.2009.24.8724 20458058.

47. Steller MA, Zou Z, Schiller JT, Baserga R. Transformation by human papillomavirus 16 E6 and E7: role of the insulin-like growth factor 1 receptor. Cancer Res. 1996;56(21):5087–91. 8895768.

48. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425–34. doi: 10.1016/S1470-2045(08)70103-7 18407790.

49. Harris TG, Burk RD, Yu H, Minkoff H, Massad LS, Watts DH, et al. Insulin-like growth factor axis and oncogenic human papillomavirus natural history. Cancer Epidemiol Biomarkers Prev. 2008;17(1):245–8. doi: 10.1158/1055-9965.EPI-07-0686 18199731.

50. Horn LC, Schreiter C, Canzler A, Leonhardt K, Einenkel J, Hentschel B. CD34(low) and SMA(high) represent stromal signature in uterine cervical cancer and are markers for peritumoral stromal remodeling. Ann Diagn Pathol. 2013;17(6):531–5. doi: 10.1016/j.anndiagpath.2013.05.009 24183311.

51. Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW, et al. Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res. 2004;64(3):977–84. 14871828.

52. Diehl D, Hessel E, Oesterle D, Renner-Müller I, Elmlinger M, Langhammer M, et al. IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer. 2009;124(9):2220–5. doi: 10.1002/ijc.24193 19142966.

53. Frommer KW, Reichenmiller K, Schutt BS, Hoeflich A, Ranke MB, Dodt G, et al. IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. J Mol Endocrinol. 2006;37(1):13–23. doi: 10.1677/jme.1.01955 16901920.

54. Holmes KM, Annala M, Chua CY, Dunlap SM, Liu Y, Hugen N, et al. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad Sci U S A. 2012;109(9):3475–80. doi: 10.1073/pnas.1120375109 22345562; PubMed Central PMCID: PMCPMC3295320.

55. Schütt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol. 2004;32(3):859–68. 15171717.

56. Perks CM, Vernon EG, Rosendahl AH, Tonge D, Holly JM. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene. 2007;26(40):5966–72. doi: 10.1038/sj.onc.1210397 17369847.

57. Hodivala KJ, Pei XF, Liu QY, Jones PH, Rytina ER, Gilbert C, et al. Integrin expression and function in HPV 16-immortalised human keratinocytes in the presence or absence of v-Ha-ras. Comparison with cervical intraepithelial neoplasia. Oncogene. 1994;9(3):943–8. 8108139.

58. Galea CA, Mobli M, McNeil KA, Mulhern TD, Wallace JC, King GF, et al. Insulin-like growth factor binding protein-2: NMR analysis and structural characterization of the N-terminal domain. Biochimie. 2012;94(3):608–16. doi: 10.1016/j.biochi.2011.09.012 21951978.

59. Soh CL, McNeil K, Owczarek CM, Hardy MP, Fabri LJ, Pearse M, et al. Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer. Br J Cancer. 2014;110(12):2855–64. doi: 10.1038/bjc.2014.232 24853186; PubMed Central PMCID: PMCPMC4056053.

60. Chioni AM, Grose R. FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. J Cell Biol. 2012;197(6):801–17. doi: 10.1083/jcb.201108077 22665522; PubMed Central PMCID: PMCPMC3373409.

61. Kaipparettu BA, Kuiatse I, Tak-Yee Chan B, Benny Kaipparettu M, Lee AV, Oesterreich S. Novel egg white-based 3-D cell culture system. Biotechniques. 2008;45(2):165–8, 70–1. doi: 10.2144/000112883 18687065.

62. Pickard A, Cichon AC, Menges C, Patel D, McCance DJ. Regulation of epithelial differentiation and proliferation by the stroma: a role for the retinoblastoma protein. J Invest Dermatol. 2012;132(12):2691–9. doi: 10.1038/jid.2012.201 22696061; PubMed Central PMCID: PMCPMC3443514.

63. Tang S, Tao M, McCoy JP, Zheng ZM. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J Virol. 2006;80(9):4249–63. doi: 10.1128/JVI.80.9.4249–4263.2006 16611884; PubMed Central PMCID: PMCPMC1472016.

64. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol. 2007;27(13):4784–95. doi: 10.1128/MCB.00494-07 17470557; PubMed Central PMCID: PMCPMC1951481.

65. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther. 2005;12(1):90–100. doi: 10.1038/sj.cgt.7700775 15499378.

66. McDade SS, Patel D, Moran M, Campbell J, Fenwick K, Kozarewa I, et al. Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress. Nucleic Acids Res. 2014. doi: 10.1093/nar/gku299 24823795.